Nimenrix
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Meningococcal groups A, C, W-135 and Y conjugate vaccine
- Made by
- Pfizer Europe MA EEIG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Pfizer Europe MA EEIG |
|---|---|
| Active substance | Meningococcal groups A, C, W-135 and Y conjugate vaccine |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J07AH08 · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2012-04-20 |
| Last updated by the regulator | 2025-02-13 |
| EMA product number | EMEA/H/C/002226 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).